Engrail Therapeutics

About:

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Website: https://engrail.com/

Top Investors: Norwest Venture Partners, F-Prime Capital, Abrdn, Longwood Fund, Eight Roads Ventures

Description:

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Total Funding Amount:

$221M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)engrail.com

Founders:

Stephen Cunningham, Vikram Sudarsan

Number of Employees:

1-10

Last Funding Date:

2024-03-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai